Other Information
+Added: In September 2020, the Company’s Board approved our non-employee director compensation policy, a copy of which is filed herewith as Exhibit 10.2.
Exhibit Index
−Removed: Equity Distribution Agreement, dated March 27, 2020, by and among Altimmune, Inc.
−Removed: and JMP Securities LLC (incorporated by reference to Exhibit 1.1 to the Registrant’s Form 8-K filed on March 27, 2020 )
Amendment No.
4 to the Second Restated License Agreement, by and among Altimmune, Inc.
−Removed: and Janssen Vaccines & Prevention B.V., dated as of September 20, 2016
−Removed: Amendment No.
−Removed: 3 to the Second Restated License Agreement, by and among Altimmune, Inc.
−Removed: and Janssen Vaccines & Prevention B.V., dated as of April 2, 2020
+Added: and Janssen Vaccines & Prevention B.V., dated as of July 28, 2020
+Added: Non-Employee Director Compensation Policy
Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)
8 unchanged sentences
XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.
This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section.
2 unchanged sentences
ALTIMMUNE, INC.
−Removed: August 11, 2020
+Added: November 9, 2020
President and Chief Executive Officer (Principal Executive Officer)
−Removed: August 11, 2020
+Added: November 9, 2020
/s/ Will Brown
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.